Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.

Abstract	Aim: To assess the clinical features/imaging characteristics of pneumonitis reported during nationwide nivolumab postmarketing surveillance in Japan. Patients & methods: Clinical and radiological data were collected from pneumonitis cases reported during/after nivolumab treatment for melanoma or non-small-cell lung cancer. The expert central review committee evaluated each case. Results: Among 144 cases analyzed, 91 (63.2%) had radiological patterns considered typical for drug-induced pneumonitis and 53 (36.8%) patients had previously unobserved patterns with one or more atypical features, including 23 cases (16.0%) with ground glass opacity confined to the area around the tumor (peritumoral infiltration). A higher proportion of patients with (vs without) peritumoral infiltration had an antitumor response to nivolumab. Conclusion: Images of nivolumab-induced pneumonitis showed previously unobserved radiological patterns.
Authors	Tomohisa Baba, Fumikazu Sakai, Terufumi Kato, Masahiko Kusumoto, Hirotsugu Kenmotsu, Hiroaki Sugiura, Junya Tominaga, Katsunori Oikado, Masafumi Sata, Masahiro Endo, Noriyo Yanagawa, Shinichi Sasaki, Tae Iwasawa, Yoshinobu Saito, Yutaka Fujiwara, Yuichiro Ohe, Naoya Yamazaki, Takahiko Sakamoto, Takashi Koshiba, Kazuyoshi Kuwano
Journal	Future oncology (London, England) (Future Oncol) Vol. 15 Issue 16 Pg. 1911-1920 (Jun 2019) ISSN: 1744-8301 [Electronic] England
PMID	31020849 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents, Immunological Programmed Cell Death 1 Receptor Nivolumab
Topics	Aged Aged, 80 and over Antineoplastic Agents, Immunological (adverse effects, therapeutic use) Carcinoma, Non-Small-Cell Lung (complications, drug therapy) Female Humans Lung Neoplasms (complications, drug therapy) Male Melanoma (complications, drug therapy) Middle Aged Nivolumab (adverse effects, therapeutic use) Pneumonia (diagnosis, etiology) Programmed Cell Death 1 Receptor (antagonists & inhibitors) Radiography Severity of Illness Index Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!